Related Experiment Videos
New experimental and clinical data on leukaemia immunotherapy
Proceedings of the Royal Society of Medicine
|April 1, 1975
Summary
Active immunotherapy after chemoradiotherapy shows promising results for acute lymphoid leukemia (ALL) patients. Some achieve long-term remission, suggesting a potential cure and optimal treatment sequencing.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Acute lymphoid leukemia (ALL) remains a significant challenge in pediatric and adult hematologic malignancies.
- Current treatment protocols often involve intensive chemotherapy and radiotherapy, with varying long-term outcomes.
- The role of immunotherapy in improving remission rates and survival in ALL is an area of active research.
Purpose of the Study:
- To summarize the long-term results of active immunotherapy following chemoradiotherapy in acute lymphoid leukemia patients.
- To identify prognostic factors influencing remission and survival in ALL patients treated with this approach.
- To evaluate the optimal sequencing of chemotherapy and immunotherapy in preclinical models.
Main Methods:
- A randomized trial of 20 ALL patients receiving active immunotherapy post-chemoradiotherapy versus a control group.
- Actuarial analysis of remission and survival curves in 100 ALL patients.
- Multivariate analysis of prognostic factors (age, cytological type, tumor volume, leukaemic cell localization) in 200 ALL patients.
- Preclinical studies using L1210 leukemia model to assess chemotherapy-immunotherapy sequencing.
Main Results:
- Complete remission was observed in 7 out of 20 patients (35%) receiving immunotherapy after chemoradiotherapy, with follow-up of 7-10 years; none in the control group achieved this.
- Actuarial analysis indicated a plateau in remission and survival curves between 3-5 years for a subset of patients, suggesting a potential cure.
- Age, cytological type, tumor volume, and leukaemic cell localization were identified as significant prognostic factors.
- In the L1210 model, immunotherapy enhanced chemotherapy efficacy when given post-chemotherapy but reduced it when given pre-chemotherapy.
Conclusions:
- Active immunotherapy administered after chemoradiotherapy demonstrates significant potential for inducing long-term complete remission in ALL patients.
- The findings support the hypothesis of a potential cure for a subset of ALL patients with this treatment strategy.
- Optimal sequencing of chemotherapy followed by immunotherapy is crucial for maximizing therapeutic benefit in ALL treatment.